Rosco, a six-year-old Great Dane, had metastatic osteosarcoma that had spread to his other leg. But luckily, his family found out about a clinical trial at the Missouri State University Vet Hospital. He was treated with a new immunotherapy that activates his killer T-cells.
The results were remarkable. His metastasis disappeared, and Roscoe went on to live almost three more happy, cancer-free years with his family.
In the pilot study that he was part of, almost 40% of osteosarcoma patients became long-term survivors.
(
This guide explains why immunotherapy is so important for effectively fighting cancer)
In spring this year, Elias Immunotherapy completed the regulatory approval process and became one of the few immunotherapy treatments fully approved by the USDA.
This means that it's now available to help more dogs and families like Rosco's, without being part of a clinical trial.
Even more good news:
Just last month, researchers announced that a small tweak to the original chemo-free protocol pushed the 1-year survival rates to over 70%, a dramatic improvement compared to the ~35% survival seen with standard treatment.
Join our live webinar next Monday to get the latest updates on Elias Cancer Immunotherapy.
